Deep Radiomics-based Fusion Model Predicting Bevacizumab Treatment Response and Outcome in Patients With Colorectal Liver Metastases
Condition: The Characteristics of Patients With Colorectal Cancer Liver Metastasis Who Would Benefit More From Bevacizumab Intervention: Diagnostic Test: Deep radiomics-based fusion model Sponsor: Fudan University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 5, 2023 Category: Research Source Type: clinical trials
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-ov7/ ENGOT-ov80 Study)
Conditions: Ovarian Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Vulvar Cancer; Vagina Neoplasm; Clear Cell Carcinoma Interventions: Drug: Dostarlimab; Drug: Bevacizumab; Drug: Doxorubicin; Drug: Gemcitabine; Drug: Paclitaxel Sponsor: Yonsei University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 5, 2023 Category: Research Source Type: clinical trials
Deep Radiomics-based Fusion Model Predicting Bevacizumab Treatment Response and Outcome in Patients With Colorectal Liver Metastases
Condition: The Characteristics of Patients With Colorectal Cancer Liver Metastasis Who Would Benefit More From Bevacizumab Intervention: Diagnostic Test: Deep radiomics-based fusion model Sponsor: Fudan University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 5, 2023 Category: Research Source Type: clinical trials
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-ov7/ ENGOT-ov80 Study)
Conditions: Ovarian Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Vulvar Cancer; Vagina Neoplasm; Clear Cell Carcinoma Interventions: Drug: Dostarlimab; Drug: Bevacizumab; Drug: Doxorubicin; Drug: Gemcitabine; Drug: Paclitaxel Sponsor: Yonsei University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 5, 2023 Category: Research Source Type: clinical trials
Deep Radiomics-based Fusion Model Predicting Bevacizumab Treatment Response and Outcome in Patients With Colorectal Liver Metastases
Condition: The Characteristics of Patients With Colorectal Cancer Liver Metastasis Who Would Benefit More From Bevacizumab Intervention: Diagnostic Test: Deep radiomics-based fusion model Sponsor: Fudan University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 5, 2023 Category: Research Source Type: clinical trials
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-ov7/ ENGOT-ov80 Study)
Conditions: Ovarian Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Vulvar Cancer; Vagina Neoplasm; Clear Cell Carcinoma Interventions: Drug: Dostarlimab; Drug: Bevacizumab; Drug: Doxorubicin; Drug: Gemcitabine; Drug: Paclitaxel Sponsor: Yonsei University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 5, 2023 Category: Research Source Type: clinical trials
Deep Radiomics-based Fusion Model Predicting Bevacizumab Treatment Response and Outcome in Patients With Colorectal Liver Metastases
Condition: The Characteristics of Patients With Colorectal Cancer Liver Metastasis Who Would Benefit More From Bevacizumab Intervention: Diagnostic Test: Deep radiomics-based fusion model Sponsor: Fudan University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 5, 2023 Category: Research Source Type: clinical trials
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-ov7/ ENGOT-ov80 Study)
Conditions: Ovarian Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Vulvar Cancer; Vagina Neoplasm; Clear Cell Carcinoma Interventions: Drug: Dostarlimab; Drug: Bevacizumab; Drug: Doxorubicin; Drug: Gemcitabine; Drug: Paclitaxel Sponsor: Yonsei University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 5, 2023 Category: Research Source Type: clinical trials
Deep Radiomics-based Fusion Model Predicting Bevacizumab Treatment Response and Outcome in Patients With Colorectal Liver Metastases
Condition: The Characteristics of Patients With Colorectal Cancer Liver Metastasis Who Would Benefit More From Bevacizumab Intervention: Diagnostic Test: Deep radiomics-based fusion model Sponsor: Fudan University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 5, 2023 Category: Research Source Type: clinical trials
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-ov7/ ENGOT-ov80 Study)
Conditions: Ovarian Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Vulvar Cancer; Vagina Neoplasm; Clear Cell Carcinoma Interventions: Drug: Dostarlimab; Drug: Bevacizumab; Drug: Doxorubicin; Drug: Gemcitabine; Drug: Paclitaxel Sponsor: Yonsei University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 5, 2023 Category: Research Source Type: clinical trials
